Whole-genome sequencing to understand hidradenitis suppurativa in diverse groups
Official title: Whole genome sequencing analysis of hidradenitis suppurativa
Funded at Henry Ford Health + Michigan State University Health Sciences · NIH-11404883 · Data updated 2026-11-12
Researchers will study the genetic factors that contribute to hidradenitis suppurativa, especially in African American, Hispanic/Latino, and White patients, to better understand why some people are more affected.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Henry Ford Health + Michigan State University Health Sciences NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $636,297 |
| NIH project number | 5R01AR083553-03 |
| Project ID | NIH-11404883 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with hidradenitis suppurativa, especially from African American, Hispanic/Latino, and White populations, who consent to genomic research.
✕Less likely to help
Participants who decline genetic research or whose data do not reveal useful genetic associations may not receive direct benefit.
What this research studies
This project will analyze the entire genome of people with hidradenitis suppurativa to find genetic differences that might explain why the disease affects certain groups more than others. By combining newly generated data with existing genetic resources, the team aims to identify genetic risk factors that contribute to HS and its disparities. The work will involve sequencing DNA from diverse patient cohorts and comparing variants across groups to see which genetic differences associate with HS risk and severity. The goal is to build a clearer picture of HS biology that could guide future diagnostics and therapies. Participation would involve genetic analysis from consenting participants and access to existing data resources.
Why it matters
Potential benefit: If successful, the research could lead to better understanding of HS causes and ultimately more precise, personalized approaches to prevention and treatment.
How similar studies have gone: Past genetic studies of HS have been limited, with only one broad genetic association study published, making this work particularly novel and potentially impactful.
Where this research is happening
-
Henry Ford Health + Michigan State University Health Sciences
East Lansing, United States Active
Researchers
- Principal investigator: Mi, Qing-Sheng — Henry Ford Health + Michigan State University Health Sciences
- Study coordinator: Mi, Qing-Sheng
Related research
Other NIH-funded projects on the same topics.
-
Anti-CD38 immunotherapy for severe hidradenitis suppurativa
A new treatment using anti-CD38 therapy is being tested for people with severe hidradenitis suppurativa who have not responded to prior therapies.
-
Botulinum toxin blocks nerve signals to immune cells to treat hidradenitis suppurativa
This NIH grant tests a new approach to hidradenitis suppurativa by using botulinum toxin to interrupt nerve signals that may drive skin inflammation in patients.
-
Precision therapies for hidradenitis suppurativa using AI
A doctor-researcher team at UC San Francisco is using advanced computer methods to find personalized drug options to treat hidradenitis suppurativa.
-
Injectable Hydrogel for HS: a localized therapy to ease painful skin disease
A new baricitinib hydrogel is being developed to deliver pain relief and reduce inflammation directly in hidradenitis suppurativa (HS) lesions, potentially lowering systemic side effects.
-
Understanding the Genes Behind Hidradenitis Suppurativa in teens and young adults
A study to find genetic factors that contribute to hidradenitis suppurativa (HS), a painful skin condition that often starts in adolescence and affects many Black individuals.
-
Cortisol Synthesis and HS Tunnel Disease in 3D Skin Models
Aims to understand how cortisol production and signaling affect the painful tunnels in hidradenitis suppurativa using 3D skin models and patient tissue.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.